Your browser doesn't support javascript.
loading
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu, Lucy Y; Strassner, James P; Refat, Maggi A; Harris, John E; King, Brett A.
Afiliación
  • Liu LY; Yale University School of Medicine, New Haven, Connecticut.
  • Strassner JP; Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts.
  • Refat MA; Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts.
  • Harris JE; Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts. Electronic address: john.harris@umassmed.edu.
  • King BA; Department of Dermatology, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
J Am Acad Dermatol ; 77(4): 675-682.e1, 2017 Oct.
Article en En | MEDLINE | ID: mdl-28823882
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piperidinas / Pirimidinas / Pirroles / Terapia Ultravioleta / Vitíligo / Pigmentación de la Piel / Inhibidores de Proteínas Quinasas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piperidinas / Pirimidinas / Pirroles / Terapia Ultravioleta / Vitíligo / Pigmentación de la Piel / Inhibidores de Proteínas Quinasas Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Año: 2017 Tipo del documento: Article